Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon
Completed · Phase 4 · NCT05069597
Conditions: Cystic Fibrosis, Chronic Pancreatitis
At a glance
- Research payments reported, 2025
- $3,757
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- AbbVie
- Tested
- CREON (drug)
- Dates
- Started 2021-10-14; completion 2023-08-28
- Results posted
- Yes
Exocrine pancreatic insufficiency (EPI) is a condition that is caused by the inadequate pancreatic enzymes needed for normal digestion and is commonly associated with a wide range of chronic diseases, including cystic fibrosis (CF), chronic pancreatitis (CP), and pancreatic cancer. This study will assess clinical symptoms when participants with CF or CP are treated with Creon with alternate source of active drug. Creon is an approved drug for the treatment of EPI. This study is subject-blinded which means participants will not know the source of the study drug they are given. Approximately 30 adult participants with CF or CP will be enrolled at approximately 15 sites across the Unites Sta…
From ClinicalTrials.gov, last updated 2024-07-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $3,757 in research payments for this study in 2025 (6 payments).
Products named: Creon
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Lawrence J. Sindel, MD Allergy & Immunology · Mobile, AL
- Hadi S. Chohan, M.D. Pulmonology · Altamonte Springs, FL
- Christopher E. Forsmark, MD Gastroenterology · Gainesville, FL
- Holly C. Hanes, M.D. Pediatrics · Winston Salem, NC
- Kimberly A. Mcbennett, MD Pediatric Pulmonology · Cleveland, OH
- Shyam J. Thakkar, M.D. Gastroenterology · Morgantown, WV
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Rainbow Babies and Childrens Hospital, OH $1,300
- Wake Forest University $1,007
- Velocity Clinical Research Inc $700
- Central Florida Pulmonary Group PA $300
- West Virginia University $300
- University of Florida $150
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.